The new patent expands the robust patent portfolio covering RHB104 and RHB204ÂRedHill plans to initiate a pivotal Phase 3 study with RHB204 for the treatment of pulmonary nontuberculous mycobacteria NTM infections in the second half of 2019ÂRedHill plans t...
↧